Relationship between pretreatment specific IgE and the response to omalizumab therapy.

摘要: Background:  Omalizumab, an anti-IgE antibody, has proven efficacy in patients with moderate-to-severe and severe persistent allergic (IgE-mediated) asthma. While previous analyses have had some limited success predicting which will gain greatest benefit based on pretreatment baseline characteristics, it remains important to try improve this predictability. Methods:  Following a run-in phase, (12–75 years) inadequately controlled despite current therapy were randomized receive omalizumab or placebo for 28 weeks double-blind, parallel-group, multicenter study (INNOVATE). Univariate performed assess whether specific IgE serum levels related variables could be identified that predictive of response (n = 337) enrolled INNOVATE. Response was measured via including exacerbations, QoL, FEV1 physicians’ overall assessment. Results:  A total 305 (90.5%) sensitive more than one allergen the majority positive D1 Dermatophagoides pteronyssinus D2 farinae. Patients relatively high values D2, but these making low contribution load, appeared attain most from omalizumab. However, no consistent effect observed either IgEs individual allergens. Conclusions:  Based data, allergen-specific do not provide any better prediction treatment as compared IgE. At present, reliable method identifying who respond physician’s assessment.